12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok

Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J,
and Estey E. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid
leukemia or high-risk myelodysplastic syndrome. Cancer 2006; 106: 1090-1098.
Lewis R. Silverman, David R. McKenzie, Bercedis L. Peterson, James F. Holland, Jay T. Backstrom, C.L. Beach,
Richard A. Larson Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome:
Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24: 3895-3903.
de Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M, Jaksic B, Selleslag D, Zittoun R, and
Dardenne M. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid
leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative
Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia 1995; 9:
1805-1811.
Autolog KMT
Al-Ali HK, Brand R, van Biezen A, Finke J, Boogaerts M, Fauser AA, Egeler M, Cahn J-Y, Arnold R, Biersack H,
Niederwieser D, de Witte T. A retrospective comparison of autologous and unrelated donor hematolopoietic cell
transplantation in myelodysplastic syndrome and secondary acute meyloid leukemia: a report on behalf of the
Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Leuk
2007; 21: 1945-51.
Demuynck H, Delforge M, Verhoef GE, Zachee P, Vandenberghe P, van den Berghe H, and Boogaerts MA.
Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk
myelodysplastic syndromes. Br J Haematol. 1996; 92: 351-359.
Kroger N, Brand R, van Biezen A, Cahn JY, Slavin S, Blaise D, Sierra J, Zander A, Niederwieser D, de Witte T.
Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
Bone Marrow Transplant. 2006; 37 :183-9.
Allogen KMT
Castro-Malaspina H, Harris RE, Gajewski J, Ramsay N, Collins R, Dharan B, King R, and Deeg HJ. Unrelated
donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by
the National Marrow Donor Program. Blood 2002 ; 99:1943-51.
Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME, Sandmaier BM, Witherspoon RP, Nash
RA, Sanders JE, Bedalov A, Hansen JA, Clurman BE, Storb R, Appelbaum FR, Deeg HJ. Hematopoietic cell
transplantation in patients with myelodsyplastic syndrome or acute myeloid leukaemia arising from
myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior
therapy or antecedent hematologic disorders. Blood. 2007 ;110:1379-87.
Hallemeier CL, Girgis MD, Blum WG, Brown RA, Khoury HJ, Devine SM, Vij R, Lin HS, DiPersio JF, Adkins
DR. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous
leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy
total body irradiation and cyclophosphamide. Biol Blood Marrow Transplant. 2006 Jul;12(7):749-57.
Ho AY, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S, and Mufti GJ.
Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute
myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC)
conditioning. Blood. 2004 ;104:1616-23.
Kornblit B, Masmas T, Madsen HO, Ryder LP, Svejgaard A, Jakobsen B, Sengeløv H, Olesen G, Heilmann C,
Dickmeiss E ,Petersen SL, Vindeløv L. Haematopoietic cell transplantation with non-myeloablative conditioning
43